Nanoformulations of Anticancer FGFR Inhibitors with Improved Therapeutic Index

Fibroblast growth factor receptor (FGFR) inhibitors like ponatinib and nintedanib are clinically approved for defined cancer patient cohorts but often exert dose-limiting adverse effects. Hence, we encapsulated FGFR inhibitors ponatinib, PD173074, and nintedanib into polylactic acid nanoparticles an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nanomedicine
Autors principals: Kallus, Sebastian, Englinger, Bernhard, Senkiv, Julia, Laemmerer, Anna, Heffeter, Petra, Berger, Walter, Kowol, Christian R., Keppler, Bernhard K.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611408/
https://ncbi.nlm.nih.gov/pubmed/30121385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nano.2018.08.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars